Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the ...

Core Points - DBV Technologies has filed an addendum to the 2024 Universal Registration Document with the French market authority AMF [1] - The addendum updates the Corporate Governance Report regarding exceptional compensation granted to the CEO, pending approval at the Annual Combined General Meeting on June 11, 2025 [2] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT™), which aims to desensitize the immune system to allergens [4] - Ongoing clinical trials include Viaskin Peanut for peanut allergic toddlers and children [4] Operations and Trading - DBV Technologies is headquartered in Châtillon, France, with operations in Warren, NJ, North America [5] - The company's ordinary shares are traded on Euronext Paris and its American Depositary Shares (ADSs) on the Nasdaq Capital Market [5]

Core Points - DBV Technologies will hold its Combined General Meeting on June 11, 2025, at 02:00 p.m. CEST at its headquarters in Châtillon, France [1] - The preliminary notice with the detailed agenda and instructions for participation was published on May 07, 2025 [2] - Shareholders can access preparatory documents on the Company's website, in compliance with legal provisions [3] - Shareholders wishing to receive documents by post or electronically must request them by June 06, 2025 [4] - A live webcast of the General Meeting will be available on the Company's website, with a recorded version accessible for at least the minimum legal period [5] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions [6] - The Company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT™) [6] - DBV Technologies is conducting clinical trials for Viaskin Peanut in peanut allergic toddlers and children [6] - The Company is headquartered in Châtillon, France, with operations in Warren, NJ, and its shares are traded on Euronext Paris and Nasdaq [7]

Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [6] - The company is investigating the use of its proprietary technology platform, Viaskin, to address food allergies through epicutaneous immunotherapy (EPIT™) [6] - DBV Technologies is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for Viaskin Peanut targeting peanut allergic toddlers and children [6] Upcoming General Meeting - The Combined General Meeting is scheduled for June 11, 2025, at 02:00 p.m. CEST at the company's headquarters in Châtillon, France [1] - A preliminary notice containing the detailed agenda and draft resolutions was published on May 07, 2025, and the official meeting notice will be published on May 21, 2025 [2] - Shareholders can access preparatory documents on the company's website, and requests for documents can be made until June 06, 2025 [3][4] Webcast Information - A live webcast of the General Meeting will be available on the company's website, with a recorded version accessible within seven business days after the meeting [5]

Core Viewpoint - DBV Technologies reported its financial results for the first quarter of 2025, highlighting significant cash usage in operations and ongoing clinical trials, while also announcing a financing plan to support its product development [1][5]. Financial Highlights - Cash and cash equivalents decreased to $13.0 million as of March 31, 2025, from $32.5 million at the end of 2024, reflecting a net decrease of $19.5 million, primarily due to $19.7 million used in operating activities [4][8]. - The company incurred operating losses and negative cash flows since inception, with no product revenue generated to date [6]. Cash Flow Analysis - The net cash flow used in operating activities was $19.7 million for Q1 2025, compared to $34.7 million for the same period in 2024, indicating an improvement in cash flow management [21]. - The company received gross proceeds of $125.5 million on April 7, 2025, as part of a financing plan of up to $306.9 million to support the Viaskin® Peanut Patch [5]. Operating Income and Expenses - Operating income for Q1 2025 was $0.8 million, down from $1.4 million in Q1 2024, attributed to a lower French Research Tax Credit due to more activities being conducted in North America [10][12]. - Total operating expenses decreased to $27.4 million in Q1 2025 from $30 million in Q1 2024, mainly due to reduced General & Administrative expenses [13][15]. Net Loss - The net loss for the first quarter of 2025 was $27.1 million, slightly improved from a net loss of $27.3 million in the same quarter of 2024 [16][17]. Financial Position - As of March 31, 2025, total assets were $50.6 million, down from $65.7 million at the end of 2024, with liabilities increasing to $47.7 million from $38.3 million [18]. Company Overview - DBV Technologies is focused on developing treatment options for food allergies using its proprietary Viaskin technology, which aims to provide non-invasive immunotherapy [22]. - The company is currently conducting clinical trials for its Viaskin Peanut product targeting peanut allergies in young children [22].